<?xml version="1.0" encoding="UTF-8"?>
<FlexiPage xmlns="http://soap.sforce.com/2006/04/metadata">
    <flexiPageRegions>
        <itemInstances>
            <componentInstance>
                <componentInstanceProperties>
                    <name>collapsed</name>
                    <value>false</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>enableActionsConfiguration</name>
                    <value>false</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>enableActionsInNative</name>
                    <value>false</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>hideChatterActions</name>
                    <value>false</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>numVisibleActions</name>
                    <value>3</value>
                </componentInstanceProperties>
                <componentName>force:highlightsPanel</componentName>
                <identifier>force_highlightsPanel</identifier>
            </componentInstance>
        </itemInstances>
        <mode>Replace</mode>
        <name>header</name>
        <type>Region</type>
    </flexiPageRegions>
    <flexiPageRegions>
        <itemInstances>
            <componentInstance>
                <componentName>force:detailPanel</componentName>
                <identifier>force_detailPanel</identifier>
            </componentInstance>
        </itemInstances>
        <itemInstances>
            <componentInstance>
                <componentInstanceProperties>
                    <name>parentFieldApiName</name>
                    <value>PJN_Assistance_Program__c.Id</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>relatedListApiName</name>
                    <value>Histories</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>relatedListComponentOverride</name>
                    <value>NONE</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>rowsToDisplay</name>
                    <value>10</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>showActionBar</name>
                    <value>true</value>
                </componentInstanceProperties>
                <componentName>force:relatedListSingleContainer</componentName>
                <identifier>force_relatedListSingleContainer</identifier>
            </componentInstance>
        </itemInstances>
        <mode>Replace</mode>
        <name>main</name>
        <type>Region</type>
    </flexiPageRegions>
    <flexiPageRegions>
        <itemInstances>
            <componentInstance>
                <componentInstanceProperties>
                    <name>decorate</name>
                    <value>true</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>richTextValue</name>
                    <value>&lt;p&gt;&lt;b style=&quot;font-size: 14px;&quot;&gt;CTTP Eligibility Criteria&lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;myRARE will confirm the patient has met the following minimum requirements for Clinical Trial Transition Program (CTTP): &lt;/span&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Participated in Evinacumab trial in the US (confirmed through submission of the CTT Form or confirmation of site name and patient study ID from investigator site). &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Patient must be a resident of the US or one of its possessions or territories. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;There is no financial eligibility criteria for CTTP enrollment. &lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Following confirmation of the eligibility criteria listed, the patient will be approved for the CTTP and their benefit information and status confirmed. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;b style=&quot;font-size: 12px;&quot;&gt;Uninsured patients with income above the PAP &lt;/b&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;May be completely uninsured or have no available benefits to cover EVKEEZA and household income above the financial guidelines for PAP. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;myRARE will determine if there are any alternate coverage options available for the patient after enrollment into CTTP. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;If no alternate coverage options are identified, the patient may receive EVKEEZA for up to a 9 month supply or until alternate coverage is secured, whichever occurs first. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Upon confirmation of coverage with EVKEEZA approved by payer, the patient will transition out of CTTP and myRARE will coordinate transition logistics based on HCP preferred infusion setting and product acquisition. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;If there are no coverage options, the patient will be eligible to receive product free of charge under the CTTP for up to 9 months’ supply.&amp;nbsp;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;&lt;b style=&quot;font-size: 12px;&quot;&gt;Alternate Coverage Options for Uninsured &lt;/b&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;myRARE will determine if there are any alternate coverage options available to the patient prior to enrollment into the PAP, as outlined in SOP 1.09 Alternate Coverage Referral. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;If alternate coverage options are identified, the patient will remain in the CTTP until coverage is secured. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;If alternate coverage is not secured, and the patient is eligible the patient will be transitioned from CTTP to PAP until they no longer qualify for PAP. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Patients not eligible for PAP will be enrolled in the CTTP. Upon confirmation of coverage, the patient will transition out of CTTP and myRARE will coordinate based on infusion setting and product acquisition HCP preferences. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;If there are no coverage options, the patient will continue to be eligible to receive product free of charge under CTTP for up to 9 months.&amp;nbsp;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;&lt;b style=&quot;font-size: 12px;&quot;&gt;Insured Patients (includes Commercial and Government insured patients): &lt;/b&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Must have an insurance plan where EVKEEZA is not on formulary, PA is required and pending a payer decision, or coverage is overwise denied or delayed by the payer and is currently being pursued (confirmed via benefit investigation). &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Upon expiration of the CTTP eligibility period or confirmation of a favorable coverage decision, whichever occurs first, the patient will be transitioned out of the CTTP and my RARE will coordinate based on infusion setting and product acquisition HCP preferences.&amp;nbsp;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;After favorable coverage decision Patients with commercial insurance will be screened for commercial copay assistance as outlined in SOP 1.07 Copay Card Program Eligibility and Enrollment. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;If an unfavorable coverage decision is reached, the patient/authorized contact and provider can seek to appeal the decision. The commercially-insured patient may remain eligible for CTTP up to 9 months supply and government-insured patient may remain eligible for up to 3 months (evaluated monthly) with continued eligibility for up to an additional 3 months (evaluated monthly) if coverage has not been determined, for a total of up to 6 months, or until a favorable coverage decision is reached, whichever occurs first. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Patients with a government or commercial insurance plan that does not restrict coverage and this has been confirmed, will not be eligible for assistance or continued assistance through the CTTP regardless of whether or not the patient’s 6- or 9-month supply eligibility has been exhausted. myRARE will review commercially insured patients having unrestricted coverage for the myRARE Commercial Copay Program and will refer patients having unrestricted government or commercial insurance to alternate coverage sources for assistance SOP 1.09 Alternate Coverage Referral with their copay, if applicable. &lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span style=&quot;font-size: 12px;&quot;&gt;Patients with government or commercial insurance plans that do not cover EVKEEZA (e.g., only has generic coverage, plan does not cover biologics, EVKEEZA is specifically excluded, etc.) will be considered for transition to the PAP from CTTP.&amp;nbsp;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;i style=&quot;font-size: 12px;&quot;&gt;For further details, reference SOP 1.04 Evinacumab Clinical Trial Transition Program&lt;/i&gt;&lt;/p&gt;</value>
                </componentInstanceProperties>
                <componentName>flexipage:richText</componentName>
                <identifier>flexipage_richText</identifier>
            </componentInstance>
        </itemInstances>
        <itemInstances>
            <componentInstance>
                <componentInstanceProperties>
                    <name>parentFieldApiName</name>
                    <value>PJN_Assistance_Program__c.Id</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>relatedListApiName</name>
                    <value>AttachedContentDocuments</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>relatedListComponentOverride</name>
                    <value>NONE</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>rowsToDisplay</name>
                    <value>10</value>
                </componentInstanceProperties>
                <componentInstanceProperties>
                    <name>showActionBar</name>
                    <value>true</value>
                </componentInstanceProperties>
                <componentName>force:relatedListSingleContainer</componentName>
                <identifier>force_relatedListSingleContainer2</identifier>
            </componentInstance>
        </itemInstances>
        <mode>Replace</mode>
        <name>sidebar</name>
        <type>Region</type>
    </flexiPageRegions>
    <masterLabel>MVN - CTTP Record Page</masterLabel>
    <parentFlexiPage>flexipage__default_rec_L</parentFlexiPage>
    <sobjectType>PJN_Assistance_Program__c</sobjectType>
    <template>
        <name>flexipage:recordHomeTemplateDesktop</name>
    </template>
    <type>RecordPage</type>
</FlexiPage>
